Hongjun Yuan

Dr. Hongjun Yuan

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2018 in La radiologia medica
Verified
Journal Article
Open access
PDF file
HYHongjun Yuan
Hongjun Yuan
FLFengyong Liu
Fengyong Liu
XLXin Li
Xin Li
YGYang Guan
Yang Guan
MWMaoqiang Wang
Maoqiang Wang
Purpose To introduce the technique and investigate the clinical efficacy of transcatheter arterial chemoembolization (TACE) in combination with simultaneous DynaCT-guided radiofrequency ablation (RFA) in the treatment of solitary large hepatocellular carcinomas (HCCs) (maximal diameter > 5 cm). Materials and methods Forty-six patients who received TACE combined with simultaneous DynaCT-guided RFA for solitary large HCCs between January 2012 and August 2016 were reviewed, and the success rate, safety, local tumor progression (LTP), and overall survival (OS) were retrospectively investigated. OS and time to progression were analyzed with the Kaplan–Meier method. Results Technical success rate was 100%, average operative time for DynaCT-guided RFA was 45.3 ± 4.8 min, average radiation dose was 730.5 ± 78.8 mGy, and no life-threatening complications were observed. At 1-month follow-up enhanced MRI, complete remission was achieved in 82.6% of patients (38/46), and partial remission in 17.4% (8/46). The median follow-up period was 29.5 months (interquartile range 4.0–69.0 months). At 1, 2, and 3 years after surgery, the LTP rates were 4.3, 13.1, and 30.4%, respectively, and the OS rates were 89.1, 71.7, and 56.5%, respectively. Conclusion DynaCT-guided TACE + RFA is safe and feasible for the treatment of solitary large HCCS. TACE combined with simultaneous RFA provides a new treatment option for solitary large HCCs in which DynaCT has important clinical value.

1 January 2018 in Journal of Cancer
Verified
Journal Article
Open access
CNChao Ni
Chao Ni
ZZZiguan Zhu
Ziguan Zhu
YXYin Xin
Yin Xin
QXQingping Xie
Qingping Xie
HYHongjun Yuan
Hongjun Yuan
XSXiangyang Song
Xiangyang Song
The increasing frequency of early breast cancer cases has driven an increasing number of patients to choose immediate reconstruction with an autologous flap. Omentum-flap-based breast reconstruction is a unique strategy that is highly suitable for repairing moderate tissue defects. However, all available evidence comes from individual reports with small numbers of cases, and the overall effectiveness and safety of the procedure have yet to be reported. Here, we reported 7 cases of laparoscopically harvested omental free flap breast reconstruction and performed a systematic review to assess the applicability and safety of this approach. The data were gathered from MEDLINE, Ovid, Google Scholar and the China Knowledge Resource Integrated Database. In total, we combined 15 articles (410 cases) for analysis. The data revealed that almost all patients (87.6%) were reported to have undergone laparoscopy instead of laparotomy; pedicle flaps were used in 90.9% of the cases, while only 5 (37 cases) used free flaps for reconstruction; and 96.6% (396/410) of all reconstruction procedures were immediate. Almost all of these cases had a small tumour burden (T0/Tis/T1 59.8%; T2 36.8%), and the distribution of tumour location was similar among the four quadrants. The cosmetic outcomes were desirable in most cases (83.9%). There were 41 complications identified in the dataset: partial graft necrosis accounted for the largest percentage (41.5%) of all events, followed by skin necrosis (19.5%), haematoma (12.2%) and wound infection (9.8%). During the follow-up period, which had a short median duration, 2 cases of tumour recurrence were reported. Overall, our systematic review found that omentum-flap-based breast reconstruction could achieve a satisfactory aesthetic outcome, especially for small breasts and tissue replacement after breast-conserving surgery, and the safety of the procedure was also acceptable.

4 November 2019 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
HYHongjun Yuan
Hongjun Yuan
XLXin Li
Xin Li
JTJing Tang
Jing Tang
MZMin Zhou
Min Zhou
FLFengyong Liu
Fengyong Liu
Objectives: This study investigates the effectiveness of local application of doxorubicin(Dox)-loaded, polydopamine (PDA)- coated single crystal hematite (α- Fe2O3) nanocubes (Fe2O3-PDA-Dox) and combretastatin A-4 phosphate disodium(CA4P)in treating hepatocellular carcinoma (HCC) in rats. Methods: The magnetic characteristics and photothermal effects of the nanoparticles were determined in vitro. Tumor-bearing Sprague–Dawley rats were divided into 3 groups of 8 according to treatment: controls, transarterial chemoembolization–photothermal ablation (pTACE) (Lipidol+Fe2O3-PDA-Dox + NIR), and CA4P + pTACE (CA4P+ Lipidol+Fe2O3-PDA-Dox + NIR). Drugs were administered through the hepatic artery, and the tumors exposed to 808-nm near-infrared radiation. The Fe content of tumors was assessed using neutron activation analysis. Treatment effectiveness was assessed using heating curves, magnetic resonance imaging, pathology results, and immunohistochemical analysis. Results: The mean tumor Fe content was greater in rats treated with CA4P + pTACE (1 h, 23.72 ± 12.45 μg/g; 24 h, 14.61 ± 8.23 μg/g) than in those treated with pTACE alone (1 h, 5.66 ± 4.29 μg/g; 24 h, 2.76 ± 1.33 μg/g). The tumor T2 imaging signal was lower in rats treated with CA4P + pTACE. Following laser irradiation, the tumor temperature increased, with higher temperatures reached in the CA4P + pTACE group (62 °C vs 55 °C). Tumor cells exhibited necrosis, apoptosis, and proliferation inhibition, with greater effects in the CA4P + pTACE group. Transient liver and kidney toxicity were observed on day 3, with more severe effects after CA4P + pTACE. Conclusions: Fe2O3-PDA-Dox nanoparticles are effective for TACE–PTA. Pretreatment with CA4P increases nanoparticle uptake by tumors, increasing the treatment effectiveness without increasing hepatorenal toxicity.

19 March 2019 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
FLFengyong Liu
Fengyong Liu
XLXin Li
Xin Li
YLYangyang Li
Yangyang Li
YQYuchen Qi
Yuchen Qi
HYHongjun Yuan
Hongjun Yuan
MZMin Zhou
Min Zhou
Hepatic carcinoma (HCC) is a kind of aggressive malignancy with high levels of morbidity and mortality. Transcatheter intra-arterial (IA) injection has been recommended as an impactful local delivery method for HCC owing to the limited delivery efficiency of ordinary intravenous injection when used for clinical application. Herein, we developed a doxorubicin (DOX)-loaded and pH-responsive magnetic drug-loaded nanosystem containing single-crystal hematite (α-Fe2O3) nanocubes and pH-sensitive synthetic polydopamine (PDA) mixed with lipiodol for magnetic resonance imaging (MRI)-guided photothermal-chemoembolization treatment in an orthotopic liver cancer model. The synthesized nanosystem showed highly sensitive T2 weighted MRI contrast images owing to the stronger magnetic performance of cubical structured α-Fe2O3 NPs, and unambiguous pH-triggered drug release properties in the acidic tumor environment because of introducing the pH-sensitive PDA. Moreover, the PDA shell could provide a highly efficient photothermal cancer-killing effect under near-infrared (NIR) laser irradiation owing to its high photothermal conversion efficiency. In an orthotopic HCC rat model, the nanosystem was successfully delivered to the tumour site by IA injection. Notably, the IA administered nanosystem with NIR laser irradiation under MRI guidance showed remarkable tumor growth inhibition. These results indicate that the nanosystem platform has the potential to be used as a therapeutic agent for liver-directed IA treatment of HCC.

31 July 2018 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
HYHongjun Yuan
Hongjun Yuan
FLFengyong Liu
Fengyong Liu
XLXin Li
Xin Li
YGYang Guan
Yang Guan
MWMaoqiang Wang
Maoqiang Wang
This study investigated the safety and efficacy of transcatheter arterial chemoembolization (TACE) with simultaneous radiofrequency ablation (RFA) as treatment for adrenal metastases (AM) from hepatocellular carcinoma(HCC). The records of 63 patients with AM who were treated at our Hospital between February 2013 and August 2016 were retrospectively reviewed. Patients were divided into a TACE+RFA group (n = 38) and a control group that received TACE alone (n = 25) according to different treatment methods. The success rate, tumor control rate, and safety of these groups were compared, and survival was evaluated using the Kaplan-Meier method. All treatments could be completed technically successful in both groups. The tumor control rate at first imaging after 1 months was 92.1% (35/38) in the TACE+RFA group and 76.0% (19/25) in the TACE group(P = 0.041). The assisted local tumor control rate allowing repeated interventions in case of local recurrence was 70.0% (7/10) in the TACE+RFA group and 30.8% (4/13) in the TACE group (P = 0.039). During the follow up period, the TACE+RFA group had better survival than the TACE group at 1 year (92.1% vs. 88.0%), 2 years (73.7% vs. 64.0%), and 3 years (55.3% vs. 44.0%) (P = 0.040). The mean survival time was 26.8 ± 2.0 months (95% CI, 22.8–30.7) in the TACE+RFA group and 17.5 ± 2.2 months (95% CI, 13.1–21.8) in the TACE group. TACE+RFA led to better control of local disease progression and longer survival time than TACE alone in the treatment of AM from HCC. Although patients given TACE+RFA had more complications than those given TACE alone, these complications were easily managed.

1 February 2019 in Academic Radiology
Verified
Journal Article
Open access
HYHongjun Yuan
Hongjun Yuan
FLFengyong Liu
Fengyong Liu
XLXin Li
Xin Li
YGYang Guan
Yang Guan
MWMaoqiang Wang
Maoqiang Wang
To evaluate the method and effectiveness of Angio-CT-guided transcatheter arterial chemoembolization (TACE) immediately in combination with radiofrequency ablation (RFA) in the treatment of large hepatocellular carcinomas (HCCs; maximum enhancing diameter >5 cm). A retrospective analysis was conducted on 48 patients with solitary large HCCs who were admitted from October 2012 to June 2016 and treated by immediate combination therapy, and 48 patients with solitary large HCCs who were treated by a sequential combination (RFA at 2-4 weeks after TACE) therapy in the same period were randomly selected as controls. After treatment, the success rates of the immediately combined technique, the short-term outcomes of the immediately combined treatment (using the modified response evaluation criteria in solid tumor standard), and the survival rates were evaluated. The success rate of the immediately combined technique was 100%. The complete remission rates 1, 3, and 6 months after treatment in the study group were 58.3%༌56.2%, and 47.9%, respectively, while the corresponding complete remission rates of control group were 37.5%, 33.3%, and 27.1%, respectively. The 1-, 2-, and 3-year survival rates of the study group were 95.8%, 85.4%, and 58.3%, respectively, while the corresponding survival rates of the control group were 83.3%, 68.7%, and 43.8%, respectively. None of the patients had any serious complications. Angio-CT-guided TACE immediately in combination with RFA is a feasible, safe method for the treatment of large HCCs with excellent short-term outcomes and improved long-term prognoses.